{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:49:11Z","timestamp":1764064151431,"version":"3.45.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00108-025-01999-x","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:04:32Z","timestamp":1761145472000},"page":"1258-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der Therapie des diffusen gro\u00dfzelligen B-Zell-Lymphoms?","What is established in the treatment of diffuse large B-cell lymphoma?"],"prefix":"10.1007","volume":"66","author":[{"given":"Stefan K.","family":"Alig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"1999_CR1","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson\u00a0JS, Ku\u00a0M, Hertzberg\u00a0M et\u00a0al (2024) Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B\u2011cell lymphoma (STARGLO): a\u00a0global phase\u00a03, randomised, open-label trial. Lancet 404:1940\u20131954","journal-title":"Lancet"},{"key":"1999_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson\u00a0JS, Palomba\u00a0ML, Gordon\u00a0LI et\u00a0al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B\u2011cell lymphomas (TRANSCEND NHL 001): a\u00a0multicentre seamless design study. Lancet 396:839\u2013852","journal-title":"Lancet"},{"key":"1999_CR3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson\u00a0JS, Solomon\u00a0SR, Arnason\u00a0J et\u00a0al (2023) Lisocabtagene maraleucel as second-line therapy for large B\u2011cell lymphoma: primary analysis of the phase\u00a03 TRANSFORM study. Blood 141:1675\u20131684","journal-title":"Blood"},{"key":"1999_CR4","first-page":"1184","volume":"109","author":"PF Caimi","year":"2024","unstructured":"Caimi\u00a0PF, Ai\u00a0WZ, Alderuccio\u00a0JP et\u00a0al (2024) Loncastuximab tesirine in relapsed\/refractory diffuse large B\u2011cell lymphoma: long-term efficacy and safety from the phase\u00a0II LOTIS-2\u00a0study. Haematologica 109:1184\u20131193","journal-title":"Haematologica"},{"key":"1999_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson\u00a0MJ, Carlo-Stella\u00a0C, Morschhauser\u00a0F et\u00a0al (2022) Glofitamab for Relapsed or Refractory Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 387:2220\u20132231","journal-title":"N Engl J Med"},{"key":"1999_CR6","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","volume":"41","author":"M Elsallab","year":"2023","unstructured":"Elsallab\u00a0M, Maus\u00a0MV (2023) Expanding access to CAR T\u00a0cell therapies through local manufacturing. Nat Biotechnol 41:1698\u20131708","journal-title":"Nat Biotechnol"},{"key":"1999_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans\u00a0CP, Weisenburger\u00a0DD, Greiner\u00a0TC et\u00a0al (2004) Confirmation of the molecular classification of diffuse large B\u2011cell lymphoma by immunohistochemistry using a\u00a0tissue microarray. Blood 103:275\u2013282","journal-title":"Blood"},{"key":"1999_CR8","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot\u00a0R, Bachy\u00a0E, Cartron\u00a0G et\u00a0al (2023) Axicabtagene ciloleucel as second-line therapy in large B\u00a0cell lymphoma ineligible for autologous stem cell transplantation: a\u00a0phase\u00a02\u00a0trial. Nat Med 29:2593\u20132601","journal-title":"Nat Med"},{"key":"1999_CR9","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz\u00a0DM, Scherer\u00a0F, Jin\u00a0MC et\u00a0al (2018) Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B\u2011Cell Lymphoma. J\u00a0Clin Oncol 36:2845\u20132853","journal-title":"J Clin Oncol"},{"key":"1999_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz\u00a0DM, Soo\u00a0J, Keh\u00a0CTL et\u00a0al (2021) Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39:1537\u20131547","journal-title":"Nat Biotechnol"},{"key":"1999_CR11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy\u00a0SE, Barrans\u00a0SL, Beer\u00a0PA et\u00a0al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a\u00a0Haematological Malignancy Research Network report. Blood 135:1759\u20131771","journal-title":"Blood"},{"key":"1999_CR12","volume-title":"Onkopedia Leitlinien","author":"G Lenz","year":"2022","unstructured":"Lenz\u00a0G, Chapuy\u00a0B, Glass\u00a0B et\u00a0al (2022) Onkopedia Leitlinie DLBCL. In: Onkopedia Leitlinien, Stand Februar 2025, https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/diffuses-grosszelliges-b-zell-lymphom\/@@guideline\/html\/index.html"},{"key":"1999_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke\u00a0FL, Ghobadi\u00a0A, Jacobson\u00a0CA et\u00a0al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B\u2011cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase\u00a01\u20132\u00a0trial. Lancet Oncol 20:31\u201342","journal-title":"Lancet Oncol"},{"key":"1999_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke\u00a0FL, Miklos\u00a0DB, Jacobson\u00a0CA et\u00a0al (2022) Axicabtagene Ciloleucel as Second-Line Therapy for Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:640\u2013654","journal-title":"N Engl J Med"},{"key":"1999_CR15","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood-2023-178623","volume":"142","author":"F Morschhauser","year":"2023","unstructured":"Morschhauser\u00a0F, Leung\u00a0W, Raghavan\u00a0V et\u00a0al (2023) Deciphering the Clinical Benefit of Pola-R-CHP versus R\u2011CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study. Blood 142:3000\u20133000","journal-title":"Blood"},{"key":"1999_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu\u00a0SS, Locke\u00a0FL, Bartlett\u00a0NL et\u00a0al (2017) Axicabtagene Ciloleucel CAR T\u2011Cell Therapy in Refractory Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 377:2531\u20132544","journal-title":"N Engl J Med"},{"key":"1999_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade\u00a0F, Jardin\u00a0F, Thieblemont\u00a0C et\u00a0al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80\u00a0years with diffuse large B\u2011cell lymphoma: a\u00a0multicentre, single-arm, phase\u00a02\u00a0trial. Lancet Oncol 12:460\u2013468","journal-title":"Lancet Oncol"},{"key":"1999_CR18","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2020","unstructured":"Poeschel\u00a0V, Held\u00a0G, Ziepert\u00a0M et\u00a0al (2020) Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B\u2011cell lymphoma with favourable prognosis (FLYER): a\u00a0randomised, phase\u00a03, non-inferiority trial. Lancet 394:2271\u20132281","journal-title":"Lancet"},{"key":"1999_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS et\u00a0al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 380:45\u201356","journal-title":"N Engl J Med"},{"key":"1999_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster\u00a0SJ, Tam\u00a0CS, Borchmann\u00a0P et\u00a0al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B\u2011cell lymphomas (JULIET): a\u00a0multicentre, open-label, single-arm, phase\u00a02\u00a0study. Lancet Oncol 22:1403\u20131415","journal-title":"Lancet Oncol"},{"key":"1999_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal\u00a0A, Hoda\u00a0D, Riedell\u00a0PA et\u00a0al (2022) Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B\u2011cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase\u00a02\u00a0study. Lancet Oncol 23:1066\u20131077","journal-title":"Lancet Oncol"},{"key":"1999_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder\u00a0BJ, Kurtz\u00a0DM, Alig\u00a0SK et\u00a0al (2023) Determinants of resistance to engineered T\u00a0cell therapies targeting CD19 in large B\u00a0cell lymphomas. Cancer Cell 41:210\u2013225 e215","journal-title":"Cancer Cell"},{"key":"1999_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly\u00a0H, Morschhauser\u00a0F, Sehn\u00a0LH et\u00a0al (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:351\u2013363","journal-title":"N Engl J Med"},{"key":"1999_CR24","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ajh.27381","volume":"99","author":"AM Tun","year":"2024","unstructured":"Tun\u00a0AM, Patel\u00a0RD, St-Pierre\u00a0F et\u00a0al (2024) Anti-CD19 chimeric antigen receptor T\u2011cell therapy in older patients with relapsed or refractory large B\u2011cell lymphoma: A\u00a0multicenter study. Am J Hematol 99:1712\u20131720","journal-title":"Am J Hematol"},{"key":"1999_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00761-025-01708-1","volume":"31","author":"B Von Tresckow","year":"2025","unstructured":"Von Tresckow\u00a0B, Borchmann\u00a0P (2025) Entwicklungen in der Rezidivtherapie des diffusen gro\u00dfzelligen B\u2011Zell-Lymphoms. Die Onkol 31:543\u2013549","journal-title":"Die Onkol"},{"key":"1999_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang\u00a0SS (2023) Epidemiology and etiology of diffuse large B\u2011cell lymphoma. Semin Hematol 60:255\u2013266","journal-title":"Semin Hematol"},{"key":"1999_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","volume":"29","author":"JR Westin","year":"2023","unstructured":"Westin\u00a0JR, Locke\u00a0FL, Dickinson\u00a0M et\u00a0al (2023) Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed\/Refractory Large B\u2011Cell Lymphoma. Clin Cancer Res 29:1894\u20131905","journal-title":"Clin Cancer Res"},{"key":"1999_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin\u00a0JR, Oluwole\u00a0OO, Kersten\u00a0MJ et\u00a0al (2023) Survival with Axicabtagene Ciloleucel in Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 389:148\u2013157","journal-title":"N Engl J Med"},{"key":"1999_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"MC Zhang","year":"2023","unstructured":"Zhang\u00a0MC, Tian\u00a0S, Fu\u00a0D et\u00a0al (2023) Genetic subtype-guided immunochemotherapy in diffuse large B\u00a0cell lymphoma: The randomized GUIDANCE-01\u00a0trial. Cancer Cell 41:1705\u20131716 e1705","journal-title":"Cancer Cell"},{"key":"1999_CR30","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1002\/hon.70094_448","volume":"43","author":"HK Zieger","year":"2025","unstructured":"Zieger\u00a0HK, Neumann\u00a0MC, Shumilov\u00a0E et\u00a0al (2025) 448 | Bispecific antibodies as holding or bridging therapy before CAR\u2011T in large B\u2011Cell lymphoma. Hematol Oncol 43:e448\u201370094","journal-title":"Hematol Oncol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01999-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:46:41Z","timestamp":1764064001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01999-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1999"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01999-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"12 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.K.\u00a0Alig ist Berater f\u00fcr Foresight Diagnostics, AstraZeneca und Kite Gilead. H.C.\u00a0Reinhardt ist Berater und\/oder erhielt Honorare von Abbvie, Roche, KinSea, Vitis, Cerus, Lilly, Novartis, Takeda, AstraZeneca, Vertex, und Merck. Au\u00dferdem erhielt er Forschungsf\u00f6rderung von AstraZeneca und Gilead Pharmaceuticals und er ist Mitgr\u00fcnder von CDL Therapeutics GmbH. B.\u00a0von Tresckow ist Berater f\u00fcr AbbVie, Allogene, Amgen, BMS\/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Serb, Sobi und Takeda. B.\u00a0von Tresckow hat Honorare erhalten von AbbVie, AstraZeneca, BMS\/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche, Serb und Takeda, er erh\u00e4lt Forschungsf\u00f6rderung von Esteve (Institution), Merck Sharp & Dohme (Institution), Novartis (Institution), and Takeda (Institution); und erhielt Reise- und Kongressunterst\u00fctzung von AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, und Novartis; desweiteren ist er Mitglied von Steuerungskommittees f\u00fcr Regeneron (Institution) und Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}